BHA & Salicylic Acid Systems: Oil-Soluble Penetration & Comedolytic Concentration Guide

Overview #

pH is not just a stability parameter in BHA formulations. It is the primary performance lever — the variable that determines whether your salicylic acid actually penetrates the follicle or just sits on the stratum corneum doing very little. We get briefs every week from brand partners who want “2% salicylic acid” on-pack without specifying pH, and that’s where the conversation has to start. The difference between a product that clears congestion in four weeks and one that does nothing is often 0.5 pH units, not the concentration on the label.

The Four Variables That Actually Drive BHA Performance #

Salicylic acid is oil-soluble. That’s the whole story, and it’s also the complication. Because it partitions into sebum, it reaches the follicular environment that water-soluble acids can’t touch. But that oil-solubility also means it behaves differently in emulsion systems than AHAs do — it wants to sit in the oil phase, which affects both delivery and stability.

The four variables we evaluate on every BHA brief are: active concentration, formulation pH, vehicle polarity, and packaging oxygen exposure.

Concentration. The clinically relevant range for comedolytic activity is 0.5%–2.0%. Below 0.5%, you’re in cosmetic territory with minimal follicular impact. Above 2.0%, you’re not getting meaningfully more efficacy in most skin types — you’re just increasing irritation risk and, in some markets, triggering drug classification. In the EU, leave-on products are capped at 2% under EU Cosmetics Regulation 1223/2009. Rinse-off goes to 3%. We’ve had brand partners push for 3% leave-on and we always push back on that brief.

pH. This is where most brands get it wrong. The pKa of salicylic acid is 2.97. At pH 3.5, roughly 75% of the molecule is in the free acid (protonated) form — the form that penetrates. At pH 4.5, that drops to around 30%. At pH 5.5, you’re below 10% free acid. So when a brand asks us to formulate at pH 5.0 because “it’s gentler,” we have to explain that they’re essentially halving the active fraction compared to pH 4.0. Gentler, yes. But also significantly less effective at the follicular level.

Vehicle polarity. Salicylic acid performs best in low-polarity vehicles — hydroalcoholic toners, lightweight serums with propylene glycol or butylene glycol as co-solvents. We’ve seen it underperform in heavy emulsion bases where the oil phase traps the active and slows release. If a brand wants a rich moisturizer with BHA, we usually recommend a two-phase approach or encapsulation. More on that below.

Packaging. Salicylic acid is relatively stable compared to retinol or vitamin C, but it will degrade in the presence of moisture and heat. We require amber glass or opaque HDPE for any formulation above 1.5%. Clear PET at 40°C/75% RH — we’ve seen 8–12% active loss by week 12 in accelerated stability.

Comedolytic Mechanism and the Penetration Depth Question #

The comedolytic action of salicylic acid comes from two things working together: keratolytic loosening of the corneocyte adhesions in the follicular canal, and mild sebostatic effect at higher concentrations. The keratolytic part is well-documented. The sebostatic part is still debated — we’re not fully convinced the clinical evidence is strong enough to make that claim on-pack without regulatory pushback.

One head-to-head study worth knowing: a double-blind, randomized controlled trial (n=60, 12 weeks) comparing 2% salicylic acid at pH 3.5 versus pH 4.5 in a hydroalcoholic toner base showed a 34% reduction in non-inflammatory comedone count at pH 3.5 versus 19% at pH 4.5. Same concentration, same base, same application protocol. The only variable was pH. That’s the number we cite when brand partners ask why we’re insisting on a lower pH target.

The penetration depth question is more nuanced. Salicylic acid reaches the infundibulum reliably at 1%–2% in a suitable vehicle. Whether it reaches the deeper follicular canal depends heavily on vehicle and application method. Leave-on serums outperform rinse-off formats for follicular penetration — contact time matters. We’ve run internal comparisons between a 2% leave-on serum and a 3% rinse-off cleanser, and the leave-on wins on comedolytic outcome despite the lower concentration.

For brands interested in how BHA compares to AHA systems in exfoliation depth and mechanism, our acid exfoliation technology documentation covers the full comparison.

Decision Matrix: Matching BHA System to Product Brief #

This is the framework we use internally when a new brief comes in. It’s not exhaustive, but it covers the decisions that determine 80% of the formulation outcome.

The “professional” column is where we see the most project failures. Brands want the performance numbers but aren’t prepared for the consumer experience at pH 3.2–3.5. Tingling is expected. Visible peeling in week one is not unusual. We almost always push back on this brief unless the brand has a clear professional or clinic channel strategy.

Where Most Brands Get This Wrong #

Honestly, the single most common mistake is treating BHA concentration as the primary efficacy variable and pH as a secondary cosmetic parameter. It’s the other way around.

The second most common mistake is combining salicylic acid with niacinamide in the same phase at low pH. At pH below 4.0, niacinamide converts to nicotinic acid — which causes flushing and doesn’t deliver the barrier or brightening benefits the brand is expecting. We see this combination requested constantly. Short answer: don’t try to combine these two in the same phase at low pH. Layer them in separate steps, or formulate the niacinamide component at pH 5.5–6.0 in a separate product.

The third mistake is scale-up. This is usually where projects go sideways. We had one batch — 150kg production run of a 1.8% salicylic acid toner at pH 3.6 — where the pH drifted to 4.1 during manufacturing because the citric acid addition sequence was wrong. The batch passed visual QC. It failed efficacy benchmarking at week 6. We now require pH verification at three points during manufacturing: post-water phase, post-active addition, and post-homogenization. That protocol came directly from that failure.

Preservative systems also behave differently at low pH. Phenoxyethanol is effective down to pH 4.0 but starts losing efficacy below that. At pH 3.2–3.5, we typically rely on the pH itself as a partial preservation mechanism — at that acidity, gram-positive organisms are largely inhibited. But gram-negative organisms are more resilient. We’ve seen Pseudomonas survive at pH 3.4 in a water-rich toner base. The alcohol content matters here. Below 15% ethanol, we don’t consider pH alone sufficient preservation.

For brands building acne-focused product lines, our acne and blemish control formulation guides cover the full active ingredient toolkit beyond BHA.

Regulatory Thresholds You Need to Know Before Briefing #

The regulatory picture for salicylic acid is fragmented, and it catches brand partners off guard more often than it should.

Under EU Cosmetics Regulation 1223/2009, salicylic acid is permitted at 2.0% in leave-on face products and 3.0% in rinse-off. Products must carry the warning “not to be used on children under 3 years of age, except in shampoos” — which creates labeling complications for brands targeting family or baby-adjacent positioning. The EU also restricts use in products intended for application near mucous membranes.

In the US, salicylic acid is an FDA-monograph OTC drug active for acne at 0.5%–2.0%. That means if you’re making efficacy claims — “treats acne,” “unclogs pores” — you’re in OTC drug territory under FDA Cosmetics Guidelines, with all the associated testing, labeling, and registration requirements. Many brands want the efficacy story without the OTC classification. That’s a regulatory tightrope we help them navigate, but it requires careful claim language.

China’s NMPA Cosmetic Regulation classifies salicylic acid as a restricted ingredient. Maximum 2.0% in leave-on, with mandatory safety assessment. Products targeting acne claims in China require special cosmetic registration — a longer and more expensive pathway. We’ve had brand partners underestimate the NMPA timeline by 6–9 months on BHA-forward SKUs.

The SCCS Scientific Opinion on salicylic acid is worth reading if you’re building a dossier for EU notification. The SCCS has flagged systemic absorption concerns at higher concentrations, particularly for leave-on body products. Face products at 2% are generally considered safe, but the opinion includes caveats on frequency of use and application area that some brands miss.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask on every BHA brief, because the answers determine everything from concentration ceiling to claim language to packaging spec.

If you’re targeting EU and want leave-on with visible comedolytic results, we’re working at 1.5%–2.0%, pH 3.5–4.0, in a hydroalcoholic serum or lightweight lotion. Budget for airless or amber glass packaging — clear PET is not appropriate for this pH range and active level. Expect a 16–20 week development timeline including stability.

If you’re targeting the US OTC acne channel, we need to align on whether you’re pursuing the drug monograph pathway or staying in cosmetic territory with softer claims. The formulation itself can be identical — the difference is in labeling, testing package, and registration. We can support both, but the timelines diverge significantly.

If you’re building a sensitive-skin BHA product — lower concentration, higher pH, gentler positioning — we’d suggest 0.5%–1.0% at pH 4.2–4.5 with a calming co-active like panthenol or allantoin to offset the mild irritation potential. That’s a product that can carry “gentle exfoliation” claims without triggering OTC classification in most markets.

What to include in your brief:
– Target market(s) and regulatory pathway (cosmetic vs. OTC drug)
– Desired on-pack concentration claim and any pH preference
– Product format (toner, serum, lotion, cleanser — leave-on vs. rinse-off)
– Skin type target (sensitive, oily, acne-prone, combination)
– Packaging preference or constraints (material, format, MOQ tolerance)
– Any co-actives you want included (niacinamide, AHAs, retinol — these all affect pH strategy)
– Timeline and target unit cost range

Frequently Asked Questions #

Q: We want to put “2% salicylic acid” on the label — is that actually stable at that concentration?

Yes, 2% is stable in the right base. The issue isn’t stability at that concentration — it’s pH drift during manufacturing and shelf life. We formulate with a citrate-phosphate buffer system and verify pH at three production checkpoints. In accelerated stability at 40°C/75% RH, a properly buffered 2% system holds within ±0.2 pH units over 12 weeks.

Q: Can we combine salicylic acid with glycolic acid in the same formula?

You can, but the pH has to serve both actives — which means staying at pH 3.5–4.0. At that range, both are reasonably active. The consumer experience is more intense, so we’d recommend starting at 1% salicylic acid plus 5% glycolic rather than maxing both. We’ve run this combination successfully in a 30ml serum format with 18% ethanol as co-solvent.

Q: Our target market is China — do we need special registration for a BHA serum?

Yes. Under NMPA rules, salicylic acid is a restricted ingredient and any leave-on product containing it requires a full safety assessment and registration filing. If you’re also making acne-related claims, that triggers the special cosmetic pathway, which adds 9–12 months to your timeline versus ordinary cosmetic registration. Plan accordingly.

Q: What’s the minimum order quantity for a custom BHA serum, and does it affect formulation choices?

Our standard MOQ for a custom liquid formula is 500kg, which typically translates to 10,000–20,000 units depending on fill weight. At that MOQ, airless pump packaging adds roughly $0.50–$0.90 per unit versus a standard disc-top bottle. For sensitive-skin or lower-pH formulations where packaging integrity matters, we recommend absorbing that cost — we’ve seen active degradation in non-airless formats that undermines the whole product story.

Q: Can we use salicylic acid in an eye-area product?

We don’t recommend it, and most regulatory frameworks don’t support it. The EU specifically restricts use near mucous membranes. Even at 0.5%, the pH required for meaningful activity is too low for periorbital skin, which is thinner and more reactive. If the brief is about congestion or milia around the eye area, we’d redirect toward a very low-concentration AHA system at pH 4.5–5.0 instead. It’s a different mechanism but a safer regulatory and consumer experience position.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.